The unmet needs in diagnosis and treatment of mood disorders in children and adolescents| Volume 49, ISSUE 12, P1121-1127, June 15, 2001

Services and prevention: pharmacoepidemiology of antidepressant use


      Between 1988 and 1994, data from 3 large sites revealed a 3–5 fold increase in the prevalence of antidepressant (ATD) treatment for U.S. youths aged 2–19 years. In 1994, the ATD prevalence for youths of this age ranged from 13 per 1000 (in the HMO) to 18 per 1000 (in 2 state Medicaid systems). Males predominated in the 10–14-year-olds treated with ATDs, whereas females predominated among 15–19-year-olds. Caucasians were more than twice as likely to receive ATD therapy than their African-American counterparts. Primary care providers were the major source of ATD prescriptions for youths. The leading diagnoses in primary care were ADHD followed by depression, whereas the diagnostic order was reversed for youths who received psychiatric services. This review provides details concerning these patterns and trends in ATD treatment of youths from community-based clinical data sources. In addition, the role of these data in an expanded, comprehensive psychotropic knowledge base is discussed. Finally, the implications of an expanded knowledge base for ATD treatments are discussed in regard to generating research questions on effectiveness and safety and to improve treatment consensus within a public-health perspective.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Anonymous (1997): Pediatric Patients: Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products: proposed rule. 21 CFR Parts 201, 312, 314, and 601.

      2. Anonymous (1994): Specific requirements on content and format of labeling for human prescription drugs; Revision of ‘pediatric use’ subsection in the labeling; Final rule. US Federal Register 59(238): 64240–64250.

      3. Anonymous (1995): Section 505 (b) of the Federal Food, Drug and Cosmetic Act 21 USC 321 et seq. pp.505 (b) USC 321.

        • Committee on Drugs
        Unapproved uses of approved drugs.
        Pediatrics. 1996; 98: 143-145
      4. Department of Health and Human Services (2000): U.S. Public Health Service, Report of the Surgeon General’s Conference on Children’s Mental Health: A National Action Agenda, Washington, DC.

      5. dosReis S, Zito JM, Safer DJ, Soeken K (in press): Mental health services for foster care and supplemental security income disabled youth. Am J Public Health.

        • Engel G.L
        The need for a new medical model.
        Science. 1977; 196: 129-136
        • Farwell J.R
        • Lee Y.J
        • Hirtz D.G
        • Sulzbacher S.I
        • Ellenberg J.H
        • Nelson K.B
        Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence.
        N Engl J Med. 1990; 322: 364-369
        • Guyatt G
        • Sackett D
        • Taylor D.W
        • Chong J
        • Roberts R
        • Pugsley S
        Determining optimal therapy-randomized trials in individual patients.
        N Engl J Med. 1986; 314: 889-892
        • Jensen P.S
        • Vitiello B
        • Leonard H
        • Laughren T.P
        Child and adolescent psychopharmacology.
        Psychopharmacol Bull. 1994; 30: 3-8
        • Laughren T.P
        Regulatory issues in pediatric psychopharmacology.
        J Am Acad Child Adolesc Psychiatry. 1996; 34: 1276-1282
        • LeFever G.B
        • Dawson K.V
        • Morrow A.L
        The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools.
        Am J Public Health. 1999; 89: 1359-1364
        • Nelson R
        We need a postmarketing drug development process (commentary).
        Pharmacoepidem Drug Safety. 2000; 9: 253-255
        • Nies A.S
        • Spielberg S.P
        Principles of therapeutics.
        in: Hardman J.G Limbird L.E Goodman and Gilman’s The Pharmacological Basis of Therapeutics. McGraw Hill, New York1996: 43-62
      6. Rushton JL, Whitmire JT (2001): Pediatric stimulant and SSRI prescription trends: 1992–1998. Arch Pediatr Adolesc Med 155:560–565.

        • Safer D.J
        • Malever M
        Stimulant treatment in Maryland public schools.
        Pediatrics. 2000; 106: 533-539
        • Safer D.J
        • Zito J.M
        • Gardner J.F
        Pemoline hepatotoxicity and post-marketing surveillance.
        J Am Acad Child Adolesc Psychiatry. 2001; 40: 622-629
      7. Vitiello B (in press): Psychopharmacology for young children: Clinical needs and research opportunities. Pediatrics.

        • Vitiello B
        • Jensen P.S
        Medication development and testing in children and adolescents.
        Arch Gen Psychiatry. 1997; 54: 871-876
      8. Walsh T (1999): Clinical and epidemiological assessment of risks of desipramine (personal communication).

      9. Zito JM (in press): Pharmacoepidemiology of methylphenidate and other stimulants for the treatment of ADHD. Mental Health, United States. DHHS.

        • Zito J.M
        • dosReis S
        • Safer D.J
        • Riddle M.A
        Racial disparity in psychotropic medications prescribed for youths with medicaid insurance in Maryland.
        J Am Acad Child Adolesc Psychiatry. 1998; 37: 179-184
        • Zito J.M
        • Riddle M.A
        Psychiatric pharmacoepidemiology for children.
        Child Adolesc Psychiatric Clin North Am. 1995; 4: 77-95
        • Zito J.M
        • Safer D.J
        Sources of data for pharmacoepidemiological studies of child and adolescent psychiatric disorders.
        J Child Adolesc Psychopharmacol. 1997; 7: 237-253
        • Zito J.M
        • Safer D.J
        • dosReis S
        • Gardner J.F
        • Boles M
        • Lynch F
        Trends in the prescribing of psychotropic medications to preschoolers.
        JAMA. 2000; 283: 1025-1030
      10. Zito JM, Safer DJ, dosReis S, Gardner JF, Johnson RE, Lynch F, Boles M (1999, June): Ten year prevalence trends for psychotropic medication from two health service systems [Abstract]. Presented at the New Clinical Drug Evaluation Meeting, Boca Raton, Florida.

        • Zito J.M
        • Safer D.J
        • Riddle M.A
        • Johnson R.E
        • Speedie S.M
        • Fox M
        Prevalence variations in psychotropic treatment of children.
        J Child Adolesc Psychopharmacol. 1998; 8: 99-105
        • Zito J.M
        • Safer D.J
        Antidepressant treatment in children and adolescents.
        Curr Psychiatry Rep. 2001; 3: 115-125